Herantis Pharma Plc
Finland, Finland · Science and Engineering
This profile has not been verified by the business owner.
Information may be incomplete or outdated.
Overview
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Contact Details
info@herantis.com
Finland, Finland
Founded
2008
Employees
20-30
Categories
Keywords
#Parkinson's disease
#Neurodegenerative diseases
#Biologics
#biotech
#drug development
Companies teams usually look at after Herantis Pharma Plc
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.